Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Diagnostic Efficacy of Peripheral Blood Marker-based Molecular Diagnostic Method for Antibody-mediated Rejection (AMR) in ABO Blood Type Incompatible Kidney Transplant (ABOiKT)

NCT04541914 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT04541914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04541914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Diagnostic Efficacy of Peripheral Blood Marker-based Molecular Diagnostic Method for Antibody-mediated Rejection (AMR) in ABO Blood Type Incompatible Kidney Transplant (ABOiKT)
Lead sponsor
Seoul National University Hospital
Phase
Not applicable
Overall status
Completed
Start date
May 19, 2020
Completion date
December 31, 2023
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

abo blood type incompatible kidney transplantation, antibody-mediated rejection